Tandem Diabetes price target raised to $24 from $17 at Stifel

Stifel raised the firm’s price target on Tandem Diabetes to $24 from $17 and keeps a Hold rating on the shares. The firm recently conducted its second annual U.S. Insulin Pump Survey, the analyst tells investors. While the survey expectations suggest 2024 guidance is still achievable, out-year share losses and modest interest in Mobi and Libre integrations continues to push the firm to remain on the sidelines.